Hubei Goto BiopharmLtd Balance Sheet Health
Financial Health criteria checks 0/6
Hubei Goto BiopharmLtd has a total shareholder equity of CN¥1.0B and total debt of CN¥1.0B, which brings its debt-to-equity ratio to 98.5%. Its total assets and total liabilities are CN¥2.7B and CN¥1.7B respectively.
Key information
98.5%
Debt to equity ratio
CN¥1.02b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥130.49m |
| Equity | CN¥1.03b |
| Total liabilities | CN¥1.67b |
| Total assets | CN¥2.70b |
Recent financial health updates
No updates
Recent updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth
Oct 09
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S
Feb 28Financial Position Analysis
Short Term Liabilities: 300966's short term assets (CN¥758.3M) do not cover its short term liabilities (CN¥782.0M).
Long Term Liabilities: 300966's short term assets (CN¥758.3M) do not cover its long term liabilities (CN¥883.8M).
Debt to Equity History and Analysis
Debt Level: 300966's net debt to equity ratio (85.9%) is considered high.
Reducing Debt: 300966's debt to equity ratio has increased from 33.7% to 98.5% over the past 5 years.
Debt Coverage: 300966's debt is not well covered by operating cash flow (15%).
Interest Coverage: Insufficient data to determine if 300966's interest payments on its debt are well covered by EBIT.